EUVIMEDEUVIMED entdecken
Crossref

The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization

Malin Andersson iD, Franz Weber iD, Ferdinand Weinelt iD, Nicole Zimmermann iD, Jette Jung, Michael Zoller, Johannes Zander, Wilhelm Huisinga iD, Robin Michelet iD, Charlotte Kloft iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Malin Andersson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, Penicillanic Acid, Piperacillin. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives The MIC, determined in vitro using a fixed tazobactam concentration, is used as basis for the pharmacokinetic/pharmacodynamic (PK/PD) index of piperacillin/tazobactam. The β-lactamase inhibitor (BLI) concentration-dependent MIC (MICcBLI) represents a promising alternative PD metric accounting for varying tazobactam concentrations observed in vivo. The aim was to investigate how the effect of varying in vivo tazobactam concentrations can be incorporated through the in vitro MICcBLI as a PD metric to assess the probability of three piperacillin/tazobactam dosing regimens to achieve predefined target values.

Methods

The MICcBLI for six isolates was evaluated as function of tazobactam concentrations. Two nonlinear mixed-effects PK models for piperacillin and tazobactam were developed based on data from 44 critically ill patients. Probability of target attainment (PTA) analysis was performed, and PTA values for the PK/PD targets 100% fT > MIC and 100% fT > MICcBLI were assessed.

Results

The susceptibility against piperacillin was dependent on the tazobactam concentration for all isolates. A two-compartment PK model with inter-occasion variability on clearance (CL) and inter-individual variability on CL and both volumes, with creatinine clearance as a covariate on CL, described the PK of piperacillin and tazobactam best. The PTA analysis revealed differences between the isolates, three infusion types and the two metrics.

Conclusions

By adopting this framework, dosing optimization can be approached to provide support for the rational design of piperacillin/tazobactam dosing regimens and other β-lactam/β-lactamase combinations. The shift from the conventional MIC to a β-lactamase inhibitor concentration-dependent metric clearly improved the knowledge of the susceptibility of a pathogen against piperacillin/tazobactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase InhibitorsAnti-Bacterial AgentsPenicillanic AcidPiperacillinHumansMicrobial Sensitivity TestsPiperacillin, Tazobactam Drug CombinationMaleTazobactamMiddle AgedFemaleAgedCritical Illness

Substanzen

beta-Lactamase InhibitorsAnti-Bacterial AgentsPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationTazobactam

Autor:innen und Institutionen

  • Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
  • Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
  • Max von Pettenkofer Institute, Faculty of Medicine, Ludwig-Maximilians-Universität, Pettenkoferstraße 9a, 80366 Munich, Germany.
  • Department of Anaesthesiology, Hospital of the Ludwig-Maximilians-University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.
  • Laboratory of Dr. Brunner, Luisenstr. 7e, 78464 Konstanz, Germany.
  • Institute of Mathematics, Universität Potsdam, Karl-Liebknecht-Str. 24/25, Potsdam, 14476 Golm, Germany.

ORCID-Profile: Malin Andersson, Franz Weber, Ferdinand Weinelt, Nicole Zimmermann, Wilhelm Huisinga, Robin Michelet, Charlotte Kloft

Zitieren

APA

Andersson, M., Weber, F., Weinelt, F., Zimmermann, N., Jung, J., Zoller, M., Zander, J., Huisinga, W., Michelet, R., & Kloft, C. (2026). The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf406

Vancouver

Andersson M, Weber F, Weinelt F, Zimmermann N, Jung J, Zoller M, et al. The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf406

BibTeX
@article{Andersson2026,
  author = {Andersson, Malin and Weber, Franz and Weinelt, Ferdinand and Zimmermann, Nicole and Jung, Jette and Zoller, Michael and Zander, Johannes and Huisinga, Wilhelm and Michelet, Robin and Kloft, Charlotte},
  title = {The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf406}
}
Kostenlos starten →